Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the 70S initiation complex.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of vancomycin-resistant Enterococcus faecium infections including bacteremia,Treatment of nosocomial pneumonia caused by Staphylococcus aureus or Streptococcus pneumoniae,Treatment of complicated skin and skin structure infections including diabetic foot infections,Treatment of uncomplicated skin and skin structure infections,Treatment of community-acquired pneumonia,Off-label: Treatment of Nocardia infections, tuberculosis as part of combination therapy, and prosthetic joint infections
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
600 mg IV every 12 hours for 10-14 days.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is approximately 5.5 hours; in patients with severe renal impairment (Cr Cl <30 m L/min), half-life may be prolonged to 7-8 hours.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Linezolid is primarily metabolized by oxidation of the morpholine ring to form two inactive metabolites: aminoethoxyacetic acid and hydroxyethyl glycine. The exact enzyme system is not fully characterized, but it is believed to be non-enzymatic or via minor cytochrome P450 pathways.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal excretion accounts for approximately 30% of the dose as unchanged drug; nonrenal clearance (likely hepatic metabolism) accounts for about 70%. Fecal excretion is minimal (<2%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Approximately 31% bound to plasma proteins, primarily albumin (about 29%) and alpha-1-acid glycoprotein (about 10%).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Steady-state volume of distribution is approximately 0.7 L/kg, indicating extensive distribution into well-perfused tissues (e.g., lungs, skin, muscle, and bone).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral bioavailability is approximately 100%, with a 600 mg oral tablet yielding AUC equivalent to a 30-minute IV infusion of 600 mg.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No dose adjustment required for any degree of renal impairment. However, the two primary metabolites may accumulate in severe renal impairment, but clinical significance is unknown.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No dose adjustment required for mild-to-moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C); use with caution.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Neonates and children <12 years: 10 mg/kg IV every 8 hours for 10-14 days. Children ≥12 years: same as adult dosing.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
No specific dose adjustment based on age alone. Monitor renal function as clearance may decrease with age, but no dose change recommended.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Linezolid is not approved for the treatment of catheter-related bloodstream infections or catheter-site infections. An increased risk of mortality was seen in patients with catheter-related bloodstream infections in a clinical trial.
None.
Myelosuppression including anemia, leukopenia, thrombocytopenia, and pancytopenia,Peripheral and optic neuropathy,Lactic acidosis,Serotonin syndrome when coadministered with serotonergic agents,Convulsions,Clostridium difficile-associated diarrhea,Hypoglycemia in diabetic patients,Development of drug-resistant bacteria,Use in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or hyperthyroidism due to tyramine interactions
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Known hypersensitivity to linezolid or any component of the formulation,Concomitant use within 2 weeks of monoamine oxidase inhibitors (MAOIs)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid tyramine-containing foods and beverages to reduce risk of hypertensive crisis. Examples: aged cheeses (cheddar, blue cheese), cured/smoked meats (pepperoni, salami), fermented foods (sauerkraut, kimchi), soy products (tofu, miso), tap beers, red wines (Chianti), and overripe fruits (avocado, bananas). Patients should adhere to a low-tyramine diet during therapy and for 2 weeks after discontinuation.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Linezolid is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetal toxicity (reduced fetal weights, increased incidence of rib and vertebral anomalies) at doses approximately equivalent to the maximum human exposure. There are no adequate and well-controlled studies in pregnant women. In the first trimester, use only if potential benefit justifies potential risk to the fetus. In the second and third trimesters, limited data suggest no increased risk of major malformations, but potential for fetal effects due to maternal toxicity exists.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Linezolid is excreted in human milk. The milk-to-plasma (M/P) ratio is approximately 0.8. The estimated infant dose is about 1.3-1.4 mg/kg/day, which is less than 5% of the maternal therapeutic dose. However, due to potential for adverse effects (e.g., myelosuppression, peripheral neuropathy), caution is advised. Breastfeeding is not recommended during therapy and for 2-3 half-lives (approximately 12-18 hours) after the last dose.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Physiologic changes in pregnancy (increased volume of distribution, increased renal clearance) may affect linezolid pharmacokinetics. However, no formal dose adjustment studies in pregnancy. Standard adult dosing (600 mg IV or PO every 12 hours) is generally used. Consider monitoring serum levels (therapeutic trough 2-8 mcg/m L) if available, especially in severe infections. Dose adjustments may be necessary based on renal function (creatinine clearance <30 m L/min) but pregnancy-specific adjustments not established.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Linezolid is a reversible nonselective monoamine oxidase inhibitor (MAOI). Avoid concomitant use with serotonergic agents (e.g., SSRIs, SNRIs, triptans) due to risk of serotonin syndrome. Monitor for myelosuppression (especially thrombocytopenia) with prolonged therapy; complete blood counts should be checked weekly. Use with caution in uncontrolled hypertension, pheochromocytoma, or carcinoid syndrome due to potential for pressor response. Linezolid exhibits 100% oral bioavailability; intravenous form is used when oral route is not feasible.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Avoid tyramine-rich foods and beverages (e.g., aged cheeses, cured meats, fermented products, tap beers, red wine) to prevent hypertensive crisis.,Report any signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle twitching) or bleeding (easy bruising, petechiae).,Take exactly as prescribed; do not stop without consulting your doctor even if you feel better.,Inform all healthcare providers that you are taking linezolid, especially before surgery or receiving any new medications.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Procaterol, a beta-2 adrenergic agonist, may enhance the hypertensive effects of linezolid, an oxazolidinone antibiotic that acts as a weak, reversible monoamine oxidase inhibitor (MAOI). This additive effect on blood pressure results from increased sympathetic tone, potentially leading to hypertensive crises. Patients may experience elevated systolic and diastolic blood pressure, tachycardia, and in severe cases, hypertensive urgency or emergency, especially when systemic absorption occurs from inhaled procaterol."
"Linezolid is a reversible, nonselective monoamine oxidase inhibitor (MAOI) that inhibits the metabolism of sympathomimetic amines such as phenylpropanolamine. This leads to increased concentrations of phenylpropanolamine and enhanced adrenergic stimulation, resulting in elevated blood pressure and risk of hypertensive crisis. Clinically, patients may experience severe hypertension, tachycardia, headache, and potential end-organ damage."
"Desipramine, a tricyclic antidepressant, inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations. Linezolid, an oxazolidinone antibiotic, is a reversible, nonselective monoamine oxidase inhibitor (MAOI). Co-administration can lead to excessive serotonergic activity, potentially causing serotonin syndrome, a life-threatening condition characterized by agitation, hyperthermia, autonomic instability, neuromuscular rigidity, and altered mental status."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the 70S initiation complex.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 600 mg IV every 12 hours for 10-14 days.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Linezolid is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetal toxicity (reduced fetal weights, increased incidence of rib and vertebral an. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.